Search

The article presents the background, data and results of a study which examined the use of Exenatide once weekly versus twice daily for the treatment of type 2 diabetes. Exenatide falls into a class of antidiabetic agents which are based on potentiation of incretin action called incretin mimetics. The primary endpoint was the change in haemoglobin A1c (HbA1c) at 30 weeks. Charts presenting changes in cardiovascular parameters, incidence of adverse events and plasma glucose levels for Exenatide once a week versus twice a day are presented. A statistical analysis of the data is included. It is reported that Exenatide once weekly produced greater improvements in glycaemic control than Exenatide given twice a day.

The article offers information on an open-label randomized study which compared the efficacy of exenatide with insulin glargine titrated to glucose targets in lowering hemoglobin A1c. The study subjects, which involved adults with type 2 diabetes who had suboptimum glycaemic control, were randomly assigned to add exenatide or insulin glargine to their blood-glucose lowering regimens. Presented in details are the findings of the study. It concludes that exenatide is ideal for patients whose risk for hypoglycemia, weight loss and convenience are particular concerns.

The authors reply to letters written in response to the article "Exenatide Once Weekly Versus Twice Daily for the Treatment of Type 2 Diabetes: A Randomised, Open-label, Non-Inferiority Study," in the October 4, 2008 issue.